Rilzabrutinib 治疗 IgG4 相关疾病的 2 期试验
这项 2a 期开放标签 52 周研究纳入 27 例 IgG4 相关疾病患者(A 组为利妥昔单抗失败或不耐受者,B 组不限利妥昔单抗史),接受 rilzabrutinib 联合 2–4 周糖皮质激素逐渐减量后单药治疗。治疗结束时 70.4%(19/27)无疾病 flare 且停用糖皮质激素/免疫抑制剂,安全性可接受。
要点
- 治疗结束时 70.4%(19/27)无 flare 且停用 GC/免疫抑制剂。
- IgG4-RD RI 在第 12 周平均下降 8.3(5.8),完成 52 周者下降 10.7(6.3)。
- 严重 TEAE 2 例(1 例死亡),均判定与药物无关。
核心结论
- Rilzabrutinib 在利妥昔单抗失败/不耐受及未使用利妥昔单抗的 IgG4 相关疾病患者中安全性可接受,多数患者成功停用糖皮质激素且无疾病 flare,疾病活动度持续下降。
研究设计与样本
- 2a 期(NCT04520451)开放标签 52 周研究,纳入 2 个队列:A 组为利妥昔单抗失败或不耐受者(13 例),B 组不限利妥昔单抗史(14 例),共 27 例。
- 患者接受 rilzabrutinib 联合 2–4 周糖皮质激素逐渐减量,随后 rilzabrutinib 单药治疗至最长 52 周。
- 主要终点为首次 rilzabrutinib 给药后至治疗结束无疾病 flare 的参与者比例及安全性。
主要发现
- 治疗结束时 70.4%(19/27)的参与者无 flare 且停用糖皮质激素/免疫抑制剂。
- IgG4-RD RI 平均(SD)在第 12 周两个队列均下降 8.3(5.8),完成 52 周 rilzabrutinib 治疗的参与者(14/17)下降 10.7(6.3)。
- 严重治疗中出现的不良事件(TEAE)发生于 2 例参与者,其中 1 例导致死亡,但两事件均判定与研究药物无关。
- 最常见 TEAE 为腹泻 40.7%(11/27)、COVID-19 18.5%(5/27)和头晕 18.5%(5/27)。
关键数值与推荐
- 无 flare 且停用糖皮质激素/免疫抑制剂的比例:70.4%(19/27)。
- IgG4-RD RI 第 12 周平均下降 8.3(5.8),完成 52 周者下降 10.7(6.3)。
- 严重 TEAE 2 例(1 例死亡),均判定与药物无关;腹泻 40.7%(11/27),COVID-19 18.5%(5/27),头晕 18.5%(5/27)。
临床怎么用
- 对于利妥昔单抗失败/不耐受或未使用利妥昔单抗的 IgG4 相关疾病患者,rilzabrutinib 联合短期糖皮质激素减量可能作为 B 细胞清除治疗的潜在替代选择。
- 治疗期间需监测腹泻、COVID-19 和头晕等常见 TEAE,并注意严重不良事件的发生。
局限性
- 开放标签、单臂设计,样本量小(27 例),缺乏安慰剂对照。
- 需在更大规模、长期、安慰剂对照试验中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of the article is to assess the efficacy and safety of rilzabrutinib, an oral, reversible inhibitor of Bruton's tyrosine kinase, in participants with IgG4-related disease. METHODS: This Phase 2a (NCT04520451) open-label, 52-week study enrolled 2 cohorts of participants with IgG4-related disease: Cohort A (participants who had failed or were intolerant to rituximab) and Cohort B (participants enrolled agnostic to rituximab history). Participants received rilzabrutinib plus a 2-to-4-week glucocorticoid (GC) taper followed by rilzabrutinib alone for up to 52 weeks. Primary endpoints were the proportion of participants without disease flare following first rilzabrutinib dose until the end of treatment and safety. RESULTS: This study included 27 participants (Cohort A: 13; Cohort B: 14). At the end of treatment, 70.4% (19/27) of participants were flare-free and off GCs/immunosuppressants. Disease activity (mean [SD]), measured by IgG4-related disease Responder Index, decreased by 8.3 (5.8) at week 12 in both cohorts and by 10.7 (6.3) in participants who completed 52 weeks of rilzabrutinib (14/17). Serious treatment-emergent adverse events (TEAEs) occurred in 2 participants, 1 resulting in death, but both events were judged unrelated to the study drug. The most frequent TEAEs were diarrhoea, 40.7% (11/27); coronavirus disease 2019, 18.5% (5/27); and dizziness, 18.5% (5/27). CONCLUSIONS: Rilzabrutinib had an acceptable safety profile in patients with IgG4-related disease who had failed/ intolerant to rituximab and who were rituximab-naïve. Most participants discontinued GCs successfully without disease flares and exhibited sustained disease activity reduction. Further investigation of this potential alternative to B-cell-depleting therapies is needed in larger, long-term, placebo-controlled trials.
引用
- Stone JH, Carruthers M, Baker MC, et al. A phase 2 trial of rilzabrutinib in IgG4-related disease. Ann Rheum Dis. 2026. PMID: 42481271. doi:10.1016/j.ard.2026.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。